Efficacy of chemotherapy for comorbid cancer in patients with simultaneous double cancers: a multicenter study.

Autor: Sohda M; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. msohda@med.gunma-u.ac.jp., Yokobori T; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan., Kimura A; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan., Kosaka T; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan., Yoshida K; Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan., Hakamada K; Department of Gastrointestinal Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan., Natsugoe S; Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Taketomi A; Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Saeki H; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Shirabe K; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan., Kuwano H; Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.; Fukuoka City Hospital, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: Surgery today [Surg Today] 2023 Jan; Vol. 53 (1), pp. 98-108. Date of Electronic Publication: 2022 Aug 01.
DOI: 10.1007/s00595-022-02542-3
Abstrakt: Purpose: Anticancer drugs for double cancers are selected based on their therapeutic effects on the target cancer, but there are insufficient data on the effects of anticancer drugs on comorbid cancer. We investigated the effect of chemotherapy on comorbid cancer in patients with simultaneous double cancers.
Methods: The subjects of this retrospective study were 51 patients with simultaneous double cancers at the time of receiving systemic chemotherapy. We evaluated the types of anticancer drugs used for double cancers, the therapeutic effects on targeted and comorbid cancers, and prognoses.
Results: Disease control was achieved for 90.9% of the target cancers and 90.7% of the comorbid cancers. The prognosis was significantly better when the disease was controlled, not only in the target cancer but also in the comorbid cancer.
Conclusion: Physicians treating double cancers should develop treatment strategies focusing not only on the treatment for advanced cancer, but also on the course of comorbidities and the therapeutic effects of anticancer drugs. This study is important because it presents new possibilities to expand the indications for anticancer drugs, while allowing unnecessary clinical research to be avoided.
(© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.)
Databáze: MEDLINE
Externí odkaz: